INSM - NASDAQ
Insmed Incorporated
$103.86
+0.13%Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
At a Glance
Live SnapshotInsmed Incorporated Management Team
Ms. Sara M. Bonstein M.B.A.
Chief Financial Officer
Compensation
$1,011,958
Mr. Michael Alexander Smith J.D.
Chief Legal Officer & Corporate Secretary
Dr. Martina Flammer M.B.A., M.D.
Chief Medical Officer
Compensation
$1,114,809
Mr. Roger Adsett M.B.A.
Chief Operating Officer
Compensation
$1,256,353
Ms. S. Nicole Schaeffer M.B.A.
Chief People Strategy Officer
Compensation
$660,810
Mr. Brian K. Kaspar Ph.D.
Chief Scientific Officer
Mr. John Drayton Wise M.B.A.
Consultant
Compensation
$1,109,686
Mr. William H. Lewis J.D., M.B.A.
President, Chief Executive Officer & Chairman
Compensation
$2,118,591
Mandy Fahey
Vice President of Corporate Communications
Ms. Claire Mulhearn
Vice President of Corporate Communications
Bryan Dunn
Vice President of Investor Relations
Insmed Incorporated Insider Positioning
During the last 12 months, insiders have sold $58.67M worth of INSM shares, with no buying activity reported.
3 Months
0
0.00
74.0K
9.43M
-9.4M
-$9.43M
3-6 Months
0
0.00
39.5K
6.36M
-6.4M
-$6.36M
6-9 Months
0
0.00
76.8K
14.51M
-14.5M
-$14.51M
9-12 Months
0
0.00
268.1K
28.37M
-28.4M
-$28.37M
Top Buyers
No buying activity
Top Sellers
Flammer Martina M.D.
Officer: Chief Medical Officer
$13.75M
Lewis William
Director, Officer: Chair And Ceo
$9.66M
Sharoky Melvin Md
Director
$8.06M
Bonstein Sara
Officer: Chief Financial Officer
$7.62M
Smith Michael Alexander
Officer: Chief Legal Officer
$5.22M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $58.67M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
INSM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 04, 2025 | May 15, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 01, 2024 | May 13, 2024 | 2024 | |
DEF 14A DEF 14A N/A | March 31, 2023 | March 31, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 01, 2022 | May 11, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 01, 2021 | May 12, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 31, 2020 | May 12, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 04, 2019 | May 16, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 05, 2018 | May 15, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 07, 2017 | May 18, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.